Skip to main content

Diabetes and Medication Possession Ratio for Statin Therapy

CBE ID
0547
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

Medication Possession Ratio (MPR) for statin therapy in diabetic individuals over 18 years of age

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.9 Care Setting
      1.14 Numerator

      The sum of the days supply that fall within the measurement window for a statin fill for each patient in the denominator. Time Window: At any time during the measurement period (12 consecutive months)
      MPR Numerator:
      1. New users: For patients with no prescriptions in the 180 days prior to the measurement period, sum of:

      Days’ supply of all medications from the first prescription until the end of the measurement period.

      **Remove the days’ supply that extend past the end of the measurement period.

      2. Continuous users: For patients with 1 or more prescriptions in the 180 days prior to the measurement period, sum of:

      Days’ supply of all medications in the measurement period

      **Remove the days supply that extends past the end of the measurement period and add days supply from the previous period that apply to the current period

      1.15 Denominator

      Patients 18 - 85 years of age with diabetes mellitus and at least one Part D claim for a statin.
      MPR Denominator:
      1. New users: Number of days from the first prescription to the end of measurement period.
      2. Continuous users: Number of days from the beginning to the end of the measurement period.


      Time window: Anytime during the measurement period (12 consecutive months)

      Exclusions

      • Patients who died during the measurement period.
      • Patients who are actively enrolled in multiple plans concurrently as of the end of the measurement period.
      • Patients with a diagnosis of polycystic ovaries who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period (if medical claims (Part A/B data) are available).
      • Patients with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period (if medical claims (Part A/B data) are available).

      Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed NVCS for Medication Management 2008
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      Centers for Medicare & Medicaid Services
      Steward POC email
                Public Comments